UVM to examine impact of energy antioxidant on metabolic dysfunction in asthma

-A A +A

UVM to examine impact of energy antioxidant on metabolic dysfunction in asthma

Tue, 02/09/2021 - 5:28am -- tim

First-ever trial of advanced form of CoQ10 supplement's impact on airway function in asthmatic obese patients

Vermont Business Magazine Better known as a health supplement with energy-enhancing effects, MitoQ – an advanced form of the popular CoQ10 – can be absorbed directly into the mitochondria within human cells. For the first time, this antioxidant is going to be studied in a pilot clinical trial to determine if it can provide improved airway function in patients with asthma and obesity.

This research builds on recent studies suggesting that mitochondrial dysfunction may be particularly important in contributing to poor asthma control in obesity.

A MitoQ supplement bottle (Source: MitoQ.com)

Led by Anne Dixon, MA BM BCh, professor of medicine and a pulmonary/critical care specialist at the University of Vermont (UVM) and UVM Medical Center, in collaboration with Loretta Que, M.D., professor of medicine and pulmonary/critical care specialist at Duke University, the pilot trial has begun recruiting participants at both the UVM and Duke sites.

The 14-week, randomized, placebo-controlled, double-masked clinical trial will compare 40mg daily doses of MitoQ (Mitoquinol mesylate) against placebo in patients with obesity and poorly controlled asthma to find out if MitoQ improves airway reactivity in patients with asthma and obesity. The trial, which aims to enroll 38 volunteers, will also examine lung function, quality of life, and safety, among other outcomes. MitoQ and placebo will be provided by MitoQ Ltd. of Auckland, New Zealand.

Study volunteers who consent to the trial will participate in six visits. Participants will receive either MitoQ or a placebo and will be asked to fill out questionnaires and undergo lung function testing. Blood, urine, sputum, and nasal samples will also be collected for analysis.

“MitoQ is proud to be supporting Dr. Dixon and the important work the team at the University of Vermont Medical Center are conducting,” said William Stow, Chief Scientific Officer of MitoQ Ltd. “This novel approach has the potential to alleviate some of the significant burden and cost these conditions have on both individuals and on society.”

About MitoQ

MitoQ® is a mitochondria-targeted antioxidant which specifically targets mitochondria, the powerhouses of the cell. Because mitochondria possess a strong negative charge, positively charged MitoQ is attracted to them and accumulates inside mitochondria at concentrations hundreds of times higher compared to the outside of the cell. Regular antioxidants lack this positive charge and do not get into the mitochondria (where over 90% of free radicals are produced) in meaningful amounts. MitoQ protect the cells within the vasculature by supporting the mitochondrial free radical defence system and preventing free radicals from leaking out where they can damage proteins, lipids and DNA. MitoQ has been studied globally in numerous disease states associated with mitochondrial dysfunction including cardiovascular and metabolic health.

About Asthma and Mitochondrial Dysfunction

Obesity is a major health issue in the United States with statistics showing that obesity is on the rise. The prevalence of obesity was 39.8% and affected about 93.3 million American adults in 2015-2016. The estimated annual medical cost of obesity in the United States was $147 billion U.S. dollars in 2008 with medical bills $1,429 higher per patient for obese population compared to normal weight. This is because obesity can contribute to numerous diseases such as cancer, coronary artery disease and type II diabetes, etc.

Studies have reported that there is a link between mitochondrial dysfunction and asthma, and also between mitochondrial dysfunction and obesity. This comes as no surprise as mitochondria regulate cellular metabolism, control apoptosis and help with hormonal signalling among other processes. Aberrant mitochondrial metabolism and dysfunction can induce either asthma-like features or increase asthma severity. Because of this, it is suggested that targeting mitochondria may be a good potential way to treat patients therapeutically.

For additional UVM study information, please contact Anne Dixon, MA BM BCh, UVM professor of medicine and chief of pulmonary and critical care, at anne.dixon@uvmhealth.org .

Source: 2.8.2021 Larner College of Medicine at the University of Vermont med.uvm.edu